Despite this, use of SGLT2 inhibitors in older adults remains a concern due to the potential risk of acute kidney injury (AKI) or diabetic ketoacidosis (DKA) [26–29], partially due to its effect on volume depletion. This evidence concerns the gene SLC5A2 and acute kidney injury.